Behavioral Neuroscience – News and Features

Researchers are uncovering how brain cells are affected in Fragile X syndrome, the most common cause of inherited mental retardation.

The deal aims to develop ADX63365, an orally available drug candidate for the potential treatment of schizophrenia and other undisclosed indications.

AstraZeneca has submitted two separate supplemental New Drug Applications to the US FDA for once-daily Seroquel XR™ Extended-Release Tablets.

In a study comparing brain activity of sober alcoholics and non-addicted people making financial decisions, the group of sober alcoholics showed more impulsive neural activity.

Evotec AG and Renovis, Inc. today announced that they have entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases, in a stock-for-stock transaction valued at approximately US$ 151.8 million.

Titan Pharmaceuticals’ Phase III efficacy and safety trials demonstrate that iloperidone is associated with greater improvements in the symptoms of schizophrenia versus placebo.

Scientists have used human embryonic stem cells to predict the toxic effects of drugs and provide chemical clues to diagnosing disease.

According to Golden Helix, method implemented in its HelixTree® Software considerably increases the ability to identify rare genetic variants.

Boosting an exercise-related gene in the brain works as a powerful anti-depressant in mice, according to a Yale School of Medicine report.

SGI claims that its Altix 64-Bit system improves genomic software applications performance up to 50 percent over 32-Bit systems.